Ratings NeoGenomics, Inc.

Equities

NEO

US64049M2098

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
14.14 ^USD	+2.09%		+4.51%	-12.61%

04-18	NeoGenomics, Inc. Announces Senior Leadership Promotions	CI
04-18	NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics	CI

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
With an enterprise value anticipated at 3.19 times the sales for the current fiscal year, the company turns out to be overvalued.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NEOGENOMICS, INC.	-12.61%	1.81B		C-
SONIC HEALTHCARE LIMITED	-16.58%	8.25B		B+
RADNET, INC.	+39.20%	3.58B		C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B		B-
SYNLAB AG	-8.06%	2.46B		-
DR. LAL PATHLABS LIMITED	-6.68%	2.38B		B-
FLEURY S.A.	-19.01%	1.55B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B		C+
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B		B+
ADICON HOLDINGS LIMITED	-14.88%	1.03B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes